Senior Analyst, Consolidations and Financial Reporting
Catalent Pharma Solutions
Summary
We have an opportunity for a Senior Analyst, Consolidations and Financial Reporting to join our team. In this role, you will support the completion of monthly and quarterly consolidation tasks across Catalent's global sites. You will assist in preparing financial statements, managing intercompany activities, and supporting foreign currency translation. This position offers the chance to work closely with site finance teams to ensure accurate and timely reporting.
Job description
Position Summary
We have an opportunity for a Senior Analyst, Consolidations and Financial Reporting to join our team. In this role, you will support the completion of monthly and quarterly consolidation tasks across Catalent's global sites. You will assist in preparing financial statements, managing intercompany activities, and supporting foreign currency translation. This position offers the chance to work closely with site finance teams to ensure accurate and timely reporting.
The Role
- Assist in the completion of monthly and quarterly consolidation tasks of Catalent's 45+ global sites in OneStream, including preparing and managing top side journal entries.
- Assist in financial reporting tasks relating to the preparation and reporting of quarterly and annual financial statements internally, to banks, and other investors.
- Support in preparing the consolidated property, plant, and equipment roll forward.
- Perform intercompany review and validation, including intercompany eliminations, mismatches, settlement activity, and aging items.
- Support foreign currency translation and CTA analysis, including review of FX rates, translation impacts, and related consolidation adjustments.
- Review subsidiary submissions for completeness and accuracy, including validation of reporting packages, supplemental schedules, and required certifications.
- Partner with site finance teams to resolve reporting issues, improve data quality, and ensure timely close submissions.
- Other duties as assigned.
The Candidate
Minimum Requirements
- Bachelor's degree in accounting.
- Minimum four years of progressive experience in accounting and/or financial reporting, including Big 4/public accounting or industry experience.
- Strong understanding of US GAAP/IFRS and consolidation principles.
- Experience with multi-entity, global consolidation.
- Familiarity with tools such as Hyperion (HFM), OneStream, SAP BPC, Oracle FCCS, or similar (OneStream highly desired).
Preferred Skills & Background
- Experience in a public company environment or with SEC reporting.
Requirements
- Bachelor's degree in accounting
- Minimum four years of progressive experience in accounting and/or financial reporting, including Big 4/public accounting or industry experience
- Strong understanding of US GAAP/IFRS and consolidation principles
- Experience with multi-entity, global consolidation
- Familiarity with tools such as Hyperion (HFM), OneStream, SAP BPC, Oracle FCCS, or similar (OneStream highly desired)
Benefits
- Paid Time Off
- 8 Paid Holidays
- Medical, Dental & Vision
- 401(k) Matching
- Tuition Reimbursement
Company overview
Catalent Pharma Solutions, now known as Catalent, Inc., is a leading global contract development and manufacturing organization (CDMO) headquartered in Tampa, Florida. Founded in 2007 as a spin-off from Cardinal Health's pharmaceutical technologies segment, the company has grown into a major player in the pharmaceutical services industry. Catalent provides comprehensive drug development and manufacturing solutions including drug delivery technologies, formulation development, analytical testing, clinical and commercial manufacturing, clinical packaging, and supply chain services. The company operates over 50 facilities across four continents and has supported more than half of all FDA-approved products over the past decade. With approximately 16,900 employees, Catalent produces over 70 billion doses annually for more than 8,000 products, serving major pharmaceutical companies like Pfizer, Moderna, Novo Nordisk, and Bristol-Myers Squibb. In 2024, the company was acquired by Novo Holdings A/S for $16.5 billion, further strengthening its position in the global pharmaceutical manufacturing landscape.